Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ingram

Showing results (391-400 of 507) with videos related to

Pageof 51
Sort By:
Cancer Biology & Therapy|November 4, 2017
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcomaCaitlin D May, Sharon M Landers, Svetlana Bolshakov, et al.
Nature Communications|September 23, 2017
PD-L1 is an activation-independent marker of brown adipocytesJessica R Ingram, Michael Dougan, Mohammad Rashidian, et al.
The British Journal of Dermatology|October 12, 2023
Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort studyJohn R Ingram, Janine Bates, Rebecca Cannings-John, et al.
Dermatology and Therapy|May 15, 2025
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 TrialsJohn R Ingram, Jacek C Szepietowski, Lukasz Matusiak, et al.
The British Journal of Dermatology|February 2, 2024
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort studyHans Christian Ring, Jonathan Thorsen, Brian Kirby, et al.
Biochemistry|April 2, 1998
Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complexD L Sali, R Ingram, M Wendel, et al.
Open Biology|February 6, 2020
Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHHStephanie J Crowley, Patrick T Bruck, Md Aladdin Bhuiyan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Validation of a seven-gene predictive SIGNature for the efficacy of Immuno-Oncology PD-1 inhibitors in patients with Sarcoma (SIGNIOS)David S Moura, Jesus Lopez-Marti, Hussein Tawbi, et al.
The British Journal of Dermatology|February 16, 2024
Feasibility of daily pain measurement using text messages in hidradenitis suppurativa clinical trials; data from the THESEUS studySamar B Hasan, Janine Bates, Rebecca Cannings-John, et al.
Trials|January 28, 2015
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trialPatrick N A Harris, Anton Y Peleg, Jon Iredell, et al.
Pageof 51

Showing results (391-400 of 507) with videos related to

Sort By:
Pageof 51
Cancer Biology & Therapy|November 4, 2017
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcomaCaitlin D May, Sharon M Landers, Svetlana Bolshakov, et al.
Nature Communications|September 23, 2017
PD-L1 is an activation-independent marker of brown adipocytesJessica R Ingram, Michael Dougan, Mohammad Rashidian, et al.
The British Journal of Dermatology|October 12, 2023
Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort studyJohn R Ingram, Janine Bates, Rebecca Cannings-John, et al.
Dermatology and Therapy|May 15, 2025
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 TrialsJohn R Ingram, Jacek C Szepietowski, Lukasz Matusiak, et al.
The British Journal of Dermatology|February 2, 2024
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort studyHans Christian Ring, Jonathan Thorsen, Brian Kirby, et al.
Biochemistry|April 2, 1998
Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complexD L Sali, R Ingram, M Wendel, et al.
Open Biology|February 6, 2020
Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHHStephanie J Crowley, Patrick T Bruck, Md Aladdin Bhuiyan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Validation of a seven-gene predictive SIGNature for the efficacy of Immuno-Oncology PD-1 inhibitors in patients with Sarcoma (SIGNIOS)David S Moura, Jesus Lopez-Marti, Hussein Tawbi, et al.
The British Journal of Dermatology|February 16, 2024
Feasibility of daily pain measurement using text messages in hidradenitis suppurativa clinical trials; data from the THESEUS studySamar B Hasan, Janine Bates, Rebecca Cannings-John, et al.
Trials|January 28, 2015
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trialPatrick N A Harris, Anton Y Peleg, Jon Iredell, et al.
Pageof 51